Business Context and Reporting Period
This Form 8-K is a Current Report filed by Mangoceuticals, Inc. (Nasdaq: MGRX), a Texas corporation, on March 16, 2026. The filing primarily addresses corporate governance actions regarding executive compensation and a recent legal disclosure.
Key Financial Metrics
The filing does not contain standard financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the closing price of the Company's common stock on the effective date of the executive action:
- Stock Price (March 16, 2026): $0.45 per share.
Material Changes and Corporate Actions
Executive Option Repricing (Item 5.02)
On March 16, 2026, the Board of Directors approved a repricing of outstanding stock options held by Jacob Cohen, the Company's Chief Executive Officer and Chairman. The exercise prices were reduced to an amount exceeding the closing stock price of $0.45 per share. The specific grants affected are:
- Grant A: 50,000 shares (Original Price: $16.50; Granted: Aug 31, 2022).
- Grant B: 83,333 shares (Original Price: $4.80; Granted: Dec 28, 2023).
- Grant C: 2,000,000 shares (Original Price: $2.30; Granted: Sep 9, 2025).
Mr. Cohen recused himself from the vote. The repricing was approved by disinterested directors upon recommendation of the Compensation and Audit Committees.
Legal Proceedings (Item 7.01)
On March 17, 2026, the Company issued a press release announcing the filing of a lawsuit against a former consultant. The full details are contained in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers. It notes that actual results may differ materially from expectations due to various risks and uncertainties. No specific financial guidance or operational outlook is provided in this document. The filing explicitly states that the press release regarding the lawsuit is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific terms of the lawsuit against the former consultant in Exhibit 99.1 (Press Release dated March 17, 2026).
- Review the Amendment to Stock Option Agreements (Exhibit 10.1) to confirm the exact new exercise price and vesting terms for Mr. Cohen's options.
- Assess the impact of the option repricing on the Company's share count and potential dilution, given the significant volume of options (2.133 million total) involved.
- Check recent stock price trends to understand the magnitude of the discount provided by the repricing relative to the original grant prices.